×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BLRX – biolinerx ltd. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BLRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/8
03:21 am
blrx
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma [Yahoo! Finance]
Low
Report
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma [Yahoo! Finance]
4/8
02:30 am
blrx
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
Medium
Report
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
3/26
07:00 am
blrx
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Low
Report
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
3/25
09:02 pm
blrx
BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Medium
Report
BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
3/23
10:47 am
blrx
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/23
07:15 am
blrx
BioLineRx GAAP EPS of $0.00 beats by $0.68, revenue of $1.18M misses by $0.3M [Seeking Alpha]
High
Report
BioLineRx GAAP EPS of $0.00 beats by $0.68, revenue of $1.18M misses by $0.3M [Seeking Alpha]
3/23
07:09 am
blrx
BioLineRx Reports 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
BioLineRx Reports 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/23
07:00 am
blrx
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Medium
Report
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:01 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Yan Shaoyu
Low
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Yan Shaoyu
3/31
04:04 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: PANEM SANDRA
Medium
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: PANEM SANDRA
3/31
04:03 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Hofstein Raphael
Medium
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Hofstein Raphael
3/31
04:02 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Dar Rami
Medium
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Dar Rami
3/31
04:01 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Molcho Avraham
Medium
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Molcho Avraham
3/30
06:02 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Cohen Gal Avraham
Low
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Cohen Gal Avraham
3/30
06:02 pm
blrx
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Schwartz Aharon
Low
Report
Form 3 BioLineRx Ltd. For: Mar 18 Filed by: Schwartz Aharon
3/27
04:33 pm
blrx
Form 20-F/A BioLineRx Ltd. For: Dec 31
Medium
Report
Form 20-F/A BioLineRx Ltd. For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/6
BIOLINERX LTD/S (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
20.3%
2/19 Form CT ORDER BioLineRx Ltd. 7.5%
5/28 Form 6-K BioLineRx Ltd. For: May 28 7.0%
1/13 BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.75 price target on the stock. 6.0%
4/7 BioLineRx up big ahead of key data readout [Seeking Alpha] 4.0%
3/30 BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock. 3.9%
7/2 Form 6-K BioLineRx Ltd. For: Jul 02 2.7%
7/30 Form 20-F/A BioLineRx Ltd. For: Dec 31 2.7%
5/14 Q1/2019 3/31/2019 EPS -0.050 ZacksConsensus -0.050 ActVsEst 0.000 - In-Line 2.7%
3/12 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 2.2%
2/19 Form CT ORDER BioLineRx Ltd. 7.5%
5/28 Form 6-K BioLineRx Ltd. For: May 28 7.0%
1/13 BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.75 price target on the stock. 6.0%
4/7 BioLineRx up big ahead of key data readout [Seeking Alpha] 4.0%
3/30 BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock. 3.9%
7/2 Form 6-K BioLineRx Ltd. For: Jul 02 2.7%
7/30 Form 20-F/A BioLineRx Ltd. For: Dec 31 2.7%
5/14 Q1/2019 3/31/2019 EPS -0.050 ZacksConsensus -0.050 ActVsEst 0.000 - In-Line 2.7%
3/12 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 2.2%
TOP News Decliners
12/5
BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
-27.1%
5/7 Form 6-K BioLineRx Ltd. For: May 07 -19.8%
12/13 Form 6-K BioLineRx Ltd. For: Dec 13 -13.1%
11/5 BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients -12.9%
9/3 BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors -10.0%
8/6 BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update -8.9%
11/6 BIOLINERX LTD/S (NASDAQ: BLRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.6%
3/12 BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update -8.4%
12/14 BIOLINERX LTD/S (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -7.5%
6/28 BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares -6.8%
5/7 Form 6-K BioLineRx Ltd. For: May 07 -19.8%
12/13 Form 6-K BioLineRx Ltd. For: Dec 13 -13.1%
11/5 BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients -12.9%
9/3 BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors -10.0%
8/6 BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update -8.9%
11/6 BIOLINERX LTD/S (NASDAQ: BLRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.6%
3/12 BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update -8.4%
12/14 BIOLINERX LTD/S (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -7.5%
6/28 BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares -6.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: